First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743

G. Zalcman; Y. Oulkhouir; R. Cornelissen; L. Greillier; J. R. Rodriguez Cid; J. Mazieres; P. Briggs; A. K. Nowak; A. Tsao; N. Fujimoto; S. Peters; A. S. Mansfield; S. Popat; A. Nassar; J. Bushong; N. Hu; T. Spires; D. Balli; L. Eccles; P. Baas

doi:10.1016/j.annonc.2022.08.077

First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743

G. Zalcman, Y. Oulkhouir, R. Cornelissen, L. Greillier, J. R. Rodriguez Cid, J. Mazieres, P. Briggs, A. K. Nowak, A. Tsao, N. Fujimoto, S. Peters, A. S. Mansfield, S. Popat, A. Nassar, J. Bushong, N. Hu, T. Spires, D. Balli, L. Eccles, P. Baas

Office of DVC Research

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S1438-S1439
Number of pages	2
Journal	Annals of Oncology
Volume	33
Issue number	7
DOIs	https://doi.org/10.1016/j.annonc.2022.08.077
Publication status	Published - Sept 2022
Event	2022 Annual Meeting of the European-Society-for-Medical-Oncology - , France Duration: 9 Sept 2022 → 13 Sept 2022

Access to Document

10.1016/j.annonc.2022.08.077

Cite this

Zalcman, G., Oulkhouir, Y., Cornelissen, R., Greillier, L., Cid, J. R. R., Mazieres, J., Briggs, P., Nowak, A. K., Tsao, A., Fujimoto, N., Peters, S., Mansfield, A. S., Popat, S., Nassar, A., Bushong, J., Hu, N., Spires, T., Balli, D., Eccles, L., & Baas, P. (2022). First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743. Annals of Oncology, 33(7), S1438-S1439. https://doi.org/10.1016/j.annonc.2022.08.077

@article{73a0b84c095349c9b92f76a6ffa2c296,

title = "First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743",

author = "G. Zalcman and Y. Oulkhouir and R. Cornelissen and L. Greillier and Cid, {J. R. Rodriguez} and J. Mazieres and P. Briggs and Nowak, {A. K.} and A. Tsao and N. Fujimoto and S. Peters and Mansfield, {A. S.} and S. Popat and A. Nassar and J. Bushong and N. Hu and T. Spires and D. Balli and L. Eccles and P. Baas",

year = "2022",

month = sep,

doi = "10.1016/j.annonc.2022.08.077",

language = "English",

volume = "33",

pages = "S1438--S1439",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "7",

note = "2022 Annual Meeting of the European-Society-for-Medical-Oncology, ESMO 2022 ; Conference date: 09-09-2022 Through 13-09-2022",

}

Zalcman, G, Oulkhouir, Y, Cornelissen, R, Greillier, L, Cid, JRR, Mazieres, J, Briggs, P, Nowak, AK, Tsao, A, Fujimoto, N, Peters, S, Mansfield, AS, Popat, S, Nassar, A, Bushong, J, Hu, N, Spires, T, Balli, D, Eccles, L & Baas, P 2022, 'First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743', Annals of Oncology, vol. 33, no. 7, pp. S1438-S1439. https://doi.org/10.1016/j.annonc.2022.08.077

First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743. / Zalcman, G.; Oulkhouir, Y.; Cornelissen, R. et al.
In: Annals of Oncology, Vol. 33, No. 7, 09.2022, p. S1438-S1439.

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

TY - JOUR

T1 - First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM)

T2 - 2022 Annual Meeting of the European-Society-for-Medical-Oncology

AU - Zalcman, G.

AU - Oulkhouir, Y.

AU - Cornelissen, R.

AU - Greillier, L.

AU - Cid, J. R. Rodriguez

AU - Mazieres, J.

AU - Briggs, P.

AU - Nowak, A. K.

AU - Tsao, A.

AU - Fujimoto, N.

AU - Peters, S.

AU - Mansfield, A. S.

AU - Popat, S.

AU - Nassar, A.

AU - Bushong, J.

AU - Hu, N.

AU - Spires, T.

AU - Balli, D.

AU - Eccles, L.

AU - Baas, P.

PY - 2022/9

Y1 - 2022/9

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:000866211602487

U2 - 10.1016/j.annonc.2022.08.077

DO - 10.1016/j.annonc.2022.08.077

M3 - Abstract/Meeting Abstract

SN - 0923-7534

VL - 33

SP - S1438-S1439

JO - Annals of Oncology

JF - Annals of Oncology

IS - 7

Y2 - 9 September 2022 through 13 September 2022

ER -

First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743

Access to Document

Other files and links

Cite this